Phathom Pharmaceuticals Inc
NASDAQ:PHAT

Watchlist Manager
Phathom Pharmaceuticals Inc Logo
Phathom Pharmaceuticals Inc
NASDAQ:PHAT
Watchlist
Price: 7.5 USD -1.45% Market Closed
Market Cap: 512.9m USD
Have any thoughts about
Phathom Pharmaceuticals Inc?
Write Note

Operating Margin
Phathom Pharmaceuticals Inc

-1 096%
Current
-2 782%
Average
6.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-1 096%
=
Operating Profit
-287.9m
/
Revenue
26.3m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Phathom Pharmaceuticals Inc
NASDAQ:PHAT
512.4m USD
-1 096%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-83%
US
Eli Lilly and Co
NYSE:LLY
755.8B USD
35%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK
44%
US
Johnson & Johnson
NYSE:JNJ
351.1B USD
28%
US
Merck & Co Inc
NYSE:MRK
251.8B USD
34%
CH
Roche Holding AG
SIX:ROG
200.1B CHF
32%
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP
21%
CH
Novartis AG
SIX:NOVN
171.5B CHF
31%
US
Pfizer Inc
NYSE:PFE
151.5B USD
22%
Country US
Market Cap 512.4m USD
Operating Margin
-1 096%
Country JP
Market Cap 776 550.9T JPY
Operating Margin
-83%
Country US
Market Cap 755.8B USD
Operating Margin
35%
Country UK
Market Cap 440.4B GBP
Operating Margin
3%
Country DK
Market Cap 2.7T DKK
Operating Margin
44%
Country US
Market Cap 351.1B USD
Operating Margin
28%
Country US
Market Cap 251.8B USD
Operating Margin
34%
Country CH
Market Cap 200.1B CHF
Operating Margin
32%
Country UK
Market Cap 161.8B GBP
Operating Margin
21%
Country CH
Market Cap 171.5B CHF
Operating Margin
31%
Country US
Market Cap 151.5B USD
Operating Margin
22%
No Stocks Found

Phathom Pharmaceuticals Inc
Glance View

Market Cap
512.4m USD
Industry
Pharmaceuticals

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company is headquartered in Florham Park, New Jersey and currently employs 77 full-time employees. The company went IPO on 2019-10-25. The Company’s pipeline product candidate, vonoprazan is an oral small molecule potassium-competitive acid blocker (P-CAB). P-CABs are a class of medicines that block acid secretion in the stomach. Vonoprazan has an anti-secretory effect and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease (GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.

PHAT Intrinsic Value
9.34 USD
Undervaluation 20%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-1 096%
=
Operating Profit
-287.9m
/
Revenue
26.3m
What is the Operating Margin of Phathom Pharmaceuticals Inc?

Based on Phathom Pharmaceuticals Inc's most recent financial statements, the company has Operating Margin of -1 096%.